BMY - 134% Upside To The Bristol Myers CVR

One of my better results in 2019 has been by buying into Celgene(CELG) which was being acquired by (BMY). In that transaction, Celgene shareholders received a contingent value right or CVR which has been underestimated by the market from day one. It continues to be undervalued. The right trades with the ticker (BMYRT).

This CVR entitles its owner to receive $9.00 in cash upon FDA approval of

1. Ozanimod (by December 31, 2020) and

2. Liso-cel (JCAR017) (by December 31, 2020) and

3. Bb2121 (by March 31, 2021)

The CVR will

Read more ...